Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allo-APZ2-PAOD in Peripheral Arterial Occlusive Disease
NCT03339973Phase 2Terminated
- Sponsor
- RHEACELL
- Start
- Mar 2018
- Primary completion
- May 2020
- Modality
- Stem Cell Therapies
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in peripheral arterial occlusive disease (PAOD) comparing allo-APZ2-PAOD with Placebo (2 arms). Primary endpoints: Percent change from baseline to week 12 in total wound size of the target leg and Assessment of adverse event (AE) occurrence at 12 months. Started Mar 2018; status: terminated.
02
Drugs
EBESANAR
03
Conditions
peripheral arterial occlusive disease (PAOD)
Beyond the preview
Go deeper on NCT03339973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03339973.